Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Research & Development: 2009-2024

Historic Research & Development for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to $44.6 million.

  • Ani Pharmaceuticals' Research & Development rose 21.48% to $12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.0 million, marking a year-over-year increase of 48.27%. This contributed to the annual value of $44.6 million for FY2024, which is 30.03% up from last year.
  • As of FY2024, Ani Pharmaceuticals' Research & Development stood at $44.6 million, which was up 30.03% from $34.3 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' Research & Development ranged from a high of $44.6 million in FY2024 and a low of $11.4 million during FY2021.
  • In the last 3 years, Ani Pharmaceuticals' Research & Development had a median value of $34.3 million in 2023 and averaged $33.7 million.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Research & Development dropped by 28.95% in 2021, and later spiked by 96.31% in 2022.
  • Yearly analysis of 5 years shows Ani Pharmaceuticals' Research & Development stood at $16.0 million in 2020, then fell by 28.95% to $11.4 million in 2021, then surged by 96.31% to $22.3 million in 2022, then soared by 53.62% to $34.3 million in 2023, then skyrocketed by 30.03% to $44.6 million in 2024.